Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma

被引：8

作者：

Rezagholizadeh, Fereshteh ^{[1
,2
,3
]}

Tajik, Fatemeh ^{[4
]}

Talebi, Morteza ^{[1
,5
,6
]}

Taha, Seyed Reza ^{[4
]}

Zadeh, Mahdieh Shariat ^{[4
]}

Farhangnia, Pooya ^{[3
,7
,8
]}

Hosseini, Hamideh Sadat ^{[1
]}

Nazari, Aram ^{[1
,9
]}

Ghomi, Shabnam Mollazadeh ^{[1
,7
,9
]}

Mousavi, Seyede Mahtab Kamrani ^{[1
,10
]}

Moghaddam, Niloofar Haeri ^{[1
,10
]}

Khorramdelazad, Hossein ^{[3
,11
]}

Joghataei, Mohammad Taghi ^{[1
,2
]}

Safari, Elahe ^{[3
,8
]}

机构：

[1] Iran Univ Med Sci, Cellular & Mol Res Ctr, Tehran, Iran

[2] Iran Univ Med Sci, Fac Adv Technol Med, Dept Mol Med, Tehran, Iran

[3] Iran Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran

[4] Iran Univ Med Sci, Oncopathol Res Ctr, Tehran, Iran

[5] Iran Univ Med Sci, Fac Med, Dept Med Genet & Mol Biol, Tehran, Iran

[6] Iranian Biol Resource Ctr IBRC, Human & Anim Cell Bank, Tehran, Iran

[7] Universal Sci Educ & Res Network USERN, Immunol Board Transplantat & Cell Based Therapeut, Tehran, Iran

[8] Iran Univ Med Sci, Inst Immunol & Infect Dis, Immunol Res Ctr, Tehran, Iran

[9] Iran Univ Med Sci, Sch Med, Dept Pathol, Tehran, Iran

[10] Iran Univ Med Sci, Fac Adv Technol Med, Dept Med Nanotechnol, Tehran, Iran

[11] Rafsanjan Univ Med Sci, Sch Med, Dept Immunol, Rafsanjan, Iran

来源：

FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷

关键词：

VISTA; PDAC; CD68; pancreatic ductal adenocarcinoma; prognosis; biomarker; CD8; IMMUNE-CHECKPOINT; POOR-PROGNOSIS; T-CELLS; EXPRESSION; CTLA-4;

D O I：

10.3389/fimmu.2024.1283364

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Introduction Pancreatic cancer is a truculent disease with limited treatment options and a grim prognosis. Immunotherapy has shown promise in treating various types of cancer, but its effectiveness in pancreatic cancer has been lacking. As a result, it is crucial to identify markers associated with immunological pathways in order to improve the treatment outcomes for this deadly cancer. The purpose of this study was to investigate the diagnostic and prognostic significance of three markers, CD8, CD68, and VISTA, in pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer.Methods We analyzed gene expression data from Gene Expression Omnibus (GEO) database using bioinformatics tools. We also utilized the STRING online tool and Funrich software to study the protein-protein interactions and transcription factors associated with CD8, CD68, and VISTA. In addition, tissue microarray (TMA) and immunohistochemistry (IHC) staining were performed on 228 samples of PDAC tissue and 10 samples of normal pancreatic tissue to assess the expression levels of the markers. We then correlated these expression levels with the clinicopathological characteristics of the patients and evaluated their survival rates.Results The analysis of the GEO data revealed slightly elevated levels of VISTA in PDAC samples compared to normal tissues. However, there was a significant increase in CD68 expression and a notable reduction in CD8A expression in pancreatic cancer. Further investigation identified potential protein-protein interactions and transcription factors associated with these markers. The IHC staining of PDAC tissue samples showed an increased expression of VISTA, CD68, and CD8A in pancreatic cancer tissues. Moreover, we found correlations between the expression levels of these markers and certain clinicopathological features of the patients. Additionally, the survival analysis revealed that high expression of CD8 was associated with better disease-specific survival and progression-free survival in PDAC patients.Conclusion These findings highlight the potential of CD8, CD68, and VISTA as diagnostic and prognostic indicators in PDAC.

引用

页数：21

共 103 条

[1] Pancreatic cancer: yesterday, today and tomorrow [J].